Abstract
Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.
Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.
Methods: Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control. Results. Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects.
Conclusion: In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.
Keywords: Hematology, hematological malignancies, pain, stromal cells, syndromes, tapentadol.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy
Volume: 14 Issue: 1
Author(s): Sara Grammatico, Claudio Cartoni, Maria T. Petrucci, Pasquale Niscola, Marco Giovannini, Laura Scaramucci, Andrea Tendas, Adriana Costa, Marta Chisini, Gregorio A. Brunetti, Giada Mastrogiacomo, Sara Kiflom, Romina Talone, Giorgia Annechini, Ida Carmosino, Erminia Baldacci, Giacomo S. Morano and Giovanna Palumbo
Affiliation:
Keywords: Hematology, hematological malignancies, pain, stromal cells, syndromes, tapentadol.
Abstract: Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.
Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.
Methods: Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control. Results. Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects.
Conclusion: In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.
Export Options
About this article
Cite this article as:
Grammatico Sara, Cartoni Claudio, T. Petrucci Maria, Niscola Pasquale, Giovannini Marco, Scaramucci Laura, Tendas Andrea, Costa Adriana, Chisini Marta, A. Brunetti Gregorio, Mastrogiacomo Giada, Kiflom Sara, Talone Romina, Annechini Giorgia, Carmosino Ida, Baldacci Erminia, S. Morano Giacomo and Palumbo Giovanna, Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2016; 14 (1) . https://dx.doi.org/10.2174/1871525714666160405110833
DOI https://dx.doi.org/10.2174/1871525714666160405110833 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway
Current Pharmaceutical Design Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study
Current Rheumatology Reviews Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Discovery of Novel HDAC Inhibitors by Structure-based Optimization of Cinnamic Hydroxamic Scaffold
Letters in Drug Design & Discovery Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) New Strategies in the Chemotherapy of Leukemia: Eradicating Cancer Stem Cells in Chronic Myeloid Leukemia
Current Cancer Drug Targets Editorial [Hot Topic: New Perspectives in the Treatment of Hematological Malignancies (Guest Editor: Masahiro Kizaki)]
Current Pharmaceutical Biotechnology Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer
Current Cancer Therapy Reviews Anal Carcinoma
Current Cancer Therapy Reviews Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets On the Power of Additional and Complex Chromosomal Aberrations in CML
Current Genomics Novel Therapeutic Agents for Resistant Gram-Positive Infections
Current Drug Therapy Gene Selection from Microarray Data Using Binary Grey Wolf Algorithm for Classifying Acute Leukemia
Current Signal Transduction Therapy Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions
Current Pharmaceutical Design A Novel Technology for Hematopoietic Stem Cell Expansion Using Combination of Nanofiber and Growth Factors
Recent Patents on Nanotechnology In Search of Natural Remediation for Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Infrequent Infections in COPD
Current Respiratory Medicine Reviews Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario
Current Drug Targets Role of the Bone Marrow Microenvironment in Drug Resistance of Hematological Malignances
Current Medicinal Chemistry